ENZC (Enzolytics) Other Current Liabilities: $0.00 Mil (As of Jun. 2011)


What is Enzolytics Other Current Liabilities?

Enzolytics ENZC -12.50% Other Current Liabilities is $0.00 Mil as of Jun. 2011.

Enzolytics's other current liabilities for the quarter that ended in Jun. 2011 was $0.00 Mil.

Enzolytics's annual other current liabilities declined from Jul. 2008 ($0.02 Mil) to Dec. 2009 ($0.00 Mil) but then stayed the same from Dec. 2009 ($0.00 Mil) to Dec. 2010 ($0.00 Mil).

Enzolytics Other Current Liabilities Related Terms

Enzolytics Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Enzolytics's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enzolytics Other Current Liabilities Chart

Enzolytics Annual Data
Trend Dec07 Jul08 Dec09 Dec10
Other Current Liabilities
0.00 0.02 0.00 0.00

Enzolytics Quarterly Data
Sep07 Dec07 Apr08 Jul08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.53 0.00 0.00 0.00

Enzolytics Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $0.00 Mil mean?
Enzolytics (ENZC) has a Other Current Liabilities of $0.00 Mil as of Jun. 2011. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Enzolytics.
Is Enzolytics' Other Current Liabilities too high?
Enzolytics' current Other Current Liabilities is $0.00 Mil.
How does Enzolytics' Other Current Liabilities compare to competitors?
Enzolytics' Other Current Liabilities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Enzolytics. Enzolytics's current Other Current Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enzolytics stock overvalued right now?
Enzolytics (ENZC) has a current Other Current Liabilities of $0.00 Mil. The current Other Current Liabilities is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Enzolytics (ENZC), the current Other Current Liabilities is $0.00 Mil as of Jun. 2011. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Enzolytics Business Description

Address 1101 Raintree Circle, Suite 130, Allen, TX, USA, 75013
Enzolytics Inc is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. The company is committed to creating drugs for the good health of mankind. ENZC's flagship compound, ITV-1, is a suspension of Inactivated Pepsin Fragment (IPF), which studies have shown is effective in the treatment of HIV. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system. IPF is a platform technology that can be used to facilitate a broad range of applications. It is free from neurological, gastrointestinal and hematological side effects seen in the anti-retrovirals in use.